Fernando J Martinez,1 Ulrich Costabel,2 R Gisli Jenkins,3 John A Belperio,4 Hideya Kitamura,5 Maria Molina Molina,6 Inga Tschoepe,7 Carl Coeck,8 Thomas Haeufel,9 Manuel Quaresma,9 Vincent Cottin10 on behalf of the INBUILD trial investigators
1Weill Cornell Medicine, New York, New York, USA; 2Ruhrlandklinik, University Hospital, University of Duisburg-Essen, Essen, Germany; 3National Institute for Health Research Respiratory Biomedical Research Centre, City Campus, Nottingham University Hospital, Nottingham, UK; 4David Geffen School of Medicine at UCLA, Los Angeles, California, USA; 5Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Kanazawa-ku, Yokohama, Japan; 6ILD Unit, University Hospital of Bellvitge, IDIBELL, Barcelona, Spain; 7Elderbrook Solutions, Bietigheim-Bissingen, Germany; 8SCS Boehringer Ingelheim Comm.V., Brussels, Belgium; 9Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; 10National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Lyon, France
Introduction
- The effects of nintedanib were investigated in patients with idiopathic pulmonary fibrosis (IPF) in the two INPULSIS trials1 and in patients with other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype in the INBUILD trial.2
- In all these trials, nintedanib reduced the annual rate of decline in forced vital capacity (FVC) versus placebo. The relative reduction in the rate of FVC decline over 52 weeks was 49% in the INPULSIS trials1 and 57% in the INBUILD trial.2